Livrables
This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
First season Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc).
Third Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
Second Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference. (Month 18, Month 30, Month 40)
One manuscript submitted for publication and/or abstracts for at least one conference.Studies results will be prepared for publication/presentations. At least one manuscript and at least one abstract will be prepared and submitted to relevant journals and conferences.
Generic protocol to measure impact of the seasonal influenza vaccineThe generic protocol will include the different settings and the populations to be compared to assess the different impact effects.
Second End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Submission of article summarising the I-MOVE+ experience in evaluating the influenza vaccines, results and perspective for the future.At the end of the three year project, a summary article will be written summarising all the lessons learnt, the results of the research questions addressed (effect of previous vaccinations, duration of protection).
First Report I-Move+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings
Third Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference.
Generic protocols to measure influenza vaccine effectiveness at primary care and hospital level, using a test-negative design and screening method.The generic protocols will include a description of the study design, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, the sample size. They will specify the parts that each study site will have to document when writing the study site protocol. The generic protocols will detail the methods used and the plan of analysis to answer to specific research questions such as the effect of previous vaccinations and the duration of protection).
First Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference.
Report on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidenceA report presenting the joint analyses on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidence will be provided.
Third Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Third Report I-MOVE+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings
First season Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Third. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc).
Scientific Manuscript WP5Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications.
First End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Written report including a generic cost-effectiveness modelWritten report including a generic cost-effectiveness model which can be used among the participating countries; Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications, Month 24. As the deliverables of this work package are heavily dependent on the availability of data we want to state that we will try to include as many countries participating in WP2,3 and 4 as possible. Scotland, the Netherlands, Germany and Finland will contribute.
Third End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Second Report I-MOVE+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings
Generic protocols for effectiveness and impact studies of pneumococcal vaccinesThe generic protocols will include a description of study designs, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, sample size. They will specify the parts that each study site will have to document when writing the study site protocol. Generic protocols will detail the methods used and the plan of analysis to answer to specific research questions such as the duration of protection, magnitude of replacement etc.
First Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
Scientific manuscript WP4Scientific manuscript that presents 1) the results from the comparison of influenza VE estimates using different methods on the same database 2) Effect of previous influenza vaccinations on current influenza VE.
Training material available.A set of training material will be available on the website addressing methodological issues of studies measuring the effects of the influenza vaccine and data analysis. The training material will include presentations, case studies and programmes for data analysis.
Report with description of influenza and pneumococcal outcomes in each database.The report includes A) Descriptions of influenza outcomes in each database, including detailed information on methods used for detection and subtyping in each county. Description of information on vaccines (product name, repeated vaccination eg) and level of information on risk factors and confounders. B) The comparability of the databases is explored in order to identify a common level of detail of information in the databases, which allows register-based studies across countries.
Second Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Scientific communicationSummarise lessons learned as regards the use of electronic databases.
Second. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season the study sites will adapt the generic protocol by describing the setting in each of the seasons eg vaccines used start of vaccination campaign change in the number of GPs participating in the surveillance network etc
An I-MOVE+ website will be available with three levels of access: restricted to study sites conducting studies and ECDC, restricted to I-MOVE+ partners, and open to public. Study sites will exchange results using the restricted website area. In this restricted area, sites will update on a regular basis the number of individuals recruited in the studies. Preliminary results will be shared among relevant study sites during periodic videoconferences. The website will include a library of documents (protocols, articles, training material, videoconference minutes etc).
Publications
Auteurs:
A.M. Vilcu, C. Souty, V. Enouf, L. Capai, C. Turbelin, S. Masse, S. Behillil, M. Valette, C. Guerrisi, L. Rossignol, T. Blanchon, B. Lina, T. Hanslik, A. Falchi
Publié dans:
Clinical Microbiology and Infection, 2017, ISSN 1198-743X
Éditeur:
Blackwell Publishing Inc.
DOI:
10.1016/j.cmi.2017.09.003
Auteurs:
Marc Rondy, Amparo Larrauri, Itziar Casado, Valeria Alfonsi, Daniela Pitigoi, Odile Launay, Ritva K Syrjänen, Giedre Gefenaite, Ausenda Machado, Vesna Višekruna Vučina, Judith Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk D Marbus, Alin Gherasim, Jorge Alberto Díaz-González, Caterina Rizzo, Alina E Ivanciuc, Florence Galtier, Niina Ikonen, Aukse Mickiene, Veronica Gomez, Sanja Kure
Publié dans:
Eurosurveillance, Numéro 22/30, 2017, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.30.30580
Auteurs:
Dominic Thorrington, Edwin van Leeuwen, Mary Ramsay, Richard Pebody, Marc Baguelin
Publié dans:
BMC Medicine, Numéro 15/1, 2017, ISSN 1741-7015
Éditeur:
BioMed Central
DOI:
10.1186/s12916-017-0932-3
Auteurs:
Alin Gherasim, Iván Martínez-Baz, Jesús Castilla, Francisco Pozo, Amparo Larrauri
Publié dans:
PLOS ONE, Numéro 12/6, 2017, Page(s) e0179160, ISSN 1932-6203
Éditeur:
Public Library of Science
DOI:
10.1371/journal.pone.0179160
Auteurs:
Cécile Souty, Ana-Maria Vilcu, Lisandru Capai, Sylvie van der Werf, Martine Valette, Thierry Blanchon, Bruno Lina, Sylvie Behillil, Thomas Hanslik, Alessandra Falchi
Publié dans:
Journal of Clinical Virology, Numéro 95, 2017, Page(s) 1-4, ISSN 1386-6532
Éditeur:
Elsevier BV
DOI:
10.1016/j.jcv.2017.08.002
Auteurs:
Marc Rondy, Odile Launay, Jesus Castilla, Simona Costanzo, Joan Puig-Barberà, Giedre Gefenaite, Amparo Larrauri, Caterina Rizzo, Daniela Pitigoi, Ritva K. Syrjänen, Ausenda Machado, Sanja Kurečić Filipović, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk Marbus, Alain Moren
Publié dans:
Vaccine, Numéro 35/34, 2017, Page(s) 4298-4306, ISSN 0264-410X
Éditeur:
Elsevier BV
DOI:
10.1016/j.vaccine.2017.06.088
Auteurs:
Esther Kissling, Marta Valenciano, Francisco Pozo, Ana-Maria Vilcu, Annicka Reuss, Caterina Rizzo, Amparo Larrauri, Judit Krisztina Horváth, Mia Brytting, Lisa Domegan, Monika Korczyńska, Adam Meijer, Ausenda Machado, Alina Ivanciuc, Vesna Višekruna Vučina, Sylvie van der Werf, Brunhilde Schweiger, Antonino Bella, Alin Gherasim, Annamária Ferenczi, Katherina Zakikhany, Joan O′Donnell, Iwona
Publié dans:
Influenza and Other Respiratory Viruses, 2017, ISSN 1750-2640
Éditeur:
Blackwell Publishing Inc.
DOI:
10.1111/irv.12520
Auteurs:
Marc Rondy, Esther Kissling, Hanne-Dorthe Emborg, Alin Gherasim, Richard Pebody, Ramona Trebbien, Francisco Pozo, Amparo Larrauri, Jim McMenamin, Marta Valenciano
Publié dans:
Eurosurveillance, Numéro 23/9, 2018, ISSN 1560-7917
Éditeur:
Eurosurveillance
DOI:
10.2807/1560-7917.ES.2018.23.9.18-00086
Auteurs:
Marc Rondy, Alin Gherasim, Itziar Casado, Odile Launay, Caterina Rizzo, Daniela Pitigoi, Aukse Mickiene, Sierk D Marbus, Ausenda Machado, Ritva K Syrjänen, Iva Pem-Novose, Judith Krisztina Horváth, Amparo Larrauri, Jesús Castilla, Philippe Vanhems, Valeria Alfonsi, Alina E Ivanciuc, Monika Kuliese, Rianne van Gageldonk-Lafeber, Veronica Gomez, Niina Ikonen, Zvjezdana Lovric, Annamária Ferenczi
Publié dans:
Eurosurveillance, Numéro 22/41, 2017, ISSN 1560-7917
Éditeur:
Eurosurveillance
DOI:
10.2807/1560-7917.ES.2017.22.41.17-00645
Auteurs:
Marta Valenciano, Esther Kissling, Amparo Larrauri, Baltazar Nunes, Daniela Pitigoi, Joan O'Donnell, Annicka Reuss, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Caterina Rizzo, Alessandra Falchi, Isabelle Daviaud, Mia Brytting, Adam Meijer, Bernard Kaic, Alin Gherasim, Ausenda Machado, Alina Ivanciuc, Lisa Domegan, Brunhilde Schweiger, Annamária Ferenczi, Monika Korczyńska, Antonino B
Publié dans:
Influenza and Other Respiratory Viruses, Numéro 12/5, 2018, Page(s) 567-581, ISSN 1750-2640
Éditeur:
Blackwell Publishing Inc.
DOI:
10.1111/irv.12562
Auteurs:
Dominic Thorrington, Leo van Rossum, Mirjam Knol, Hester de Melker, Hans Rümke, Eelko Hak, Albert Jan van Hoek
Publié dans:
PLOS ONE, Numéro 13/2, 2018, Page(s) e0192640, ISSN 1932-6203
Éditeur:
Public Library of Science
DOI:
10.1371/journal.pone.0192640
Auteurs:
Omar Okasha, Hanna Rinta-Kokko, Arto A Palmu, Esa Ruokokoski, Jukka Jokinen, J Pekka Nuorti
Publié dans:
Thorax, Numéro 73/3, 2018, Page(s) 262-269, ISSN 0040-6376
Éditeur:
BMJ Publishing Group
DOI:
10.1136/thoraxjnl-2017-210440
Auteurs:
Germaine Hanquet, Pavla Krizova, Palle Valentiner-Branth, Shamez N Ladhani, J Pekka Nuorti, Agnes Lepoutre, Jolita Mereckiene, Mirjam Knol, Brita A Winje, Pilar Ciruela, Maria Ordobas, Marcela Guevara, Eisin McDonald, Eva Morfeldt, Jana Kozakova, Hans-Christian Slotved, Norman K Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary Corcoran, Arie van der Ende, Didrik F Vestrheim, Carmen Munoz-Almagro, Pe
Publié dans:
Thorax, 2018, Page(s) thoraxjnl-2018-211767, ISSN 0040-6376
Éditeur:
BMJ Publishing Group
DOI:
10.1136/thoraxjnl-2018-211767
Auteurs:
Itziar Casado, Ángela Domínguez, Diana Toledo, Judith Chamorro, Jenaro Astray, Mikel Egurrola, María Amelia Fernández-Sierra, Vicente Martín, María Morales-Suárez-Varela, Pere Godoy, Jesús Castilla
Publié dans:
Canadian Medical Association Journal, Numéro 190/1, 2018, Page(s) E3-E12, ISSN 0820-3946
Éditeur:
Canadian Medical Association/Association Medical Canadienne
DOI:
10.1503/cmaj.170910
Auteurs:
Jesús Castilla, Ana Navascués, Itziar Casado, Alejandra Pérez-García, Aitziber Aguinaga, Guillermo Ezpeleta, Francisco Pozo, Carmen Ezpeleta, Iván Martínez-Baz
Publié dans:
Eurosurveillance, Numéro 23/7, 2018, ISSN 1560-7917
Éditeur:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.7.18-00057
Auteurs:
Richard G Pebody, Mary A Sinnathamby, Fiona Warburton, Nick Andrews, Nicola L Boddington, Hongxin Zhao, Ivelina Yonova, Joanna Ellis, Elise Tessier, Matthew Donati, Alex J Elliot, Helen E Hughes, Sameera Pathirannehelage, Rachel Byford, Gillian E Smith, Simon de Lusignan, Maria Zambon
Publié dans:
Eurosurveillance, Numéro 23/25, 2018, ISSN 1560-7917
Éditeur:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.25.1700496
Auteurs:
Ana Navascués, Itziar Casado, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Yugo Floristán, Carmen Ezpeleta, Jesús Castilla
Publié dans:
Emerging Infectious Diseases, Numéro 24/7, 2018, Page(s) 1331-1334, ISSN 1080-6040
Éditeur:
US National Center for Infectious Diseases
DOI:
10.3201/eid2407.180162
Auteurs:
Adam Meijer, Corien M Swaan, Martin Voerknecht, Edin Jusic, Sharon van den Brink, Lisa A Wijsman, Bettie CG Voordouw, Gé A Donker, Jacqueline Sleven, Wendelien W Dorigo-Zetsma, Sanela Svraka, Michiel van Boven, Manon R Haverkate, Aura Timen, Jaap T van Dissel, Marion PG Koopmans, Theo M Bestebroer, Ron AM Fouchier
Publié dans:
Eurosurveillance, Numéro 23/15, 2018, ISSN 1560-7917
Éditeur:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.15.18-00160
Auteurs:
Irina Kislaya, Ana Paula Rodrigues, Mafalda Sousa-Uva, Verónica Gómez, Paulo Gonçalves, Filipe Froes, Baltazar Nunes
Publié dans:
PLOS ONE, Numéro 14/1, 2019, Page(s) e0209428, ISSN 1932-6203
Éditeur:
Public Library of Science
DOI:
10.1371/journal.pone.0209428
Auteurs:
Esther Kissling, Marc Rondy
Publié dans:
Eurosurveillance, Numéro 22/7, 2017, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.7.30464
Auteurs:
Maria-Pia Hergens, Ulrike Baum, Mia Brytting, Niina Ikonen, Anu Haveri, Åsa Wiman, Hanna Nohynek, Åke Örtqvist
Publié dans:
Eurosurveillance, Numéro 22/8, 2017, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.8.30469
Auteurs:
Jesús Castilla, Ana Navascués, Itziar Casado, Jorge Díaz-González, Alejandra Pérez-García, Leticia Fernandino, Iván Martínez-Baz, Aitziber Aguinaga, Francisco Pozo, Carmen Ezpeleta
Publié dans:
Eurosurveillance, Numéro 22/7, 2017, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.7.30465
Auteurs:
Iván Martínez-Baz, Itziar Casado, Ana Navascués, Jorge Díaz-González, Aitziber Aguinaga, Laura Barrado, Josu Delfrade, Carmen Ezpeleta, Jesús Castilla
Publié dans:
The Journal of Infectious Diseases, 2017, ISSN 0022-1899
Éditeur:
University of Chicago Press
DOI:
10.1093/infdis/jix055
Auteurs:
Hanne Dorthe Emborg, Tyra Grove Krause, Lene Nielsen, Marianne Kragh Thomsen, Claus Bohn Christiansen, Marianne Nielsine Skov, Xiaohui Chen Nielsen, Lenette Sandborg Weinreich, Thea Kølsen Fischer, Jesper Rønn, Ramona Trebbien
Publié dans:
Eurosurveillance, Numéro 21/14, 2016, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2016.21.14.30189
Auteurs:
Richard Pebody, Fiona Warburton, Joanna Ellis, Nick Andrews, Alison Potts, Simon Cottrell, Jillian Johnston, Arlene Reynolds, Rory Gunson, Catherine Thompson, Monica Galiano, Chris Robertson, David Mullett, Naomh Gallagher, Mary Sinnathamby, Ivelina Yonova, Catherine Moore, Jim McMenamin, Simon de Lusignan, Maria Zambon
Publié dans:
Eurosurveillance, Numéro 21/13, 2016, ISSN 1025-496X
Éditeur:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2016.21.13.30179
Auteurs:
Jim Mc Menamin
Publié dans:
The Parliament Magazine, 2017
Éditeur:
DODS
Auteurs:
Gómez, Verónica; Guiomar, Raquel; Rodrigues, Ana Paula; Pechirra, Pedro; Conde, Patrícia; Cristóvão, Paula; Costa, Inês; Nunes, Baltazar; Machado, Ausenda
Publié dans:
Numéro 2, 2016
Éditeur:
National Health Institute Doutor Ricardo Jorge
Auteurs:
Jim McMenamin
Publié dans:
The Parliament Magazine, Numéro Numéro 432/18 April 2016, 2016
Éditeur:
DODS
Auteurs:
Rodrigues, Ana Paula; Pechirra, Pedro; Guiomar, Raquel; Conde, Patrícia; Gomez, Verónica; Nunes, Baltazar; Machado, Ausenda
Publié dans:
Numéro 1, 2016
Éditeur:
Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
Recherche de données OpenAIRE...
Une erreur s’est produite lors de la recherche de données OpenAIRE
Aucun résultat disponible